Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone

NCT00003633 is registered in ClinicalTrials.gov with Herbert Irving Comprehensive Cancer Center as lead sponsor.

NCT NCT00003633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 1998
Completion date
Not reported
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer